
April to June 2025
| Drug Name | Government Contribution Dollars | Prescriptions |
|---|---|---|
| PEMBROLIZUMAB | $173,158,350 | 20,404 |
| ELEXACAFTOR + TEZACAFTOR + IVACAFTOR (&) IVACAFTOR | $152,357,564 | 7,500 |
| USTEKINUMAB | $133,143,338 | 19,240 |
| DUPILUMAB | $132,261,063 | 77,150 |
| AFLIBERCEPT | $121,823,246 | 123,994 |
| NIVOLUMAB | $101,874,736 | 14,221 |
| SEMAGLUTIDE | $91,113,192 | 768,087 |
| DENOSUMAB | $81,878,803 | 327,137 |
| UPADACITINIB | $78,511,494 | 53,588 |
| APIXABAN | $69,139,138 | 1,105,627 |
| OCRELIZUMAB | $59,590,576 | 3,643 |
| DARATUMUMAB | $57,298,414 | 8,021 |
| Drug Name | Government Contribution Dollars | Prescriptions |
|---|---|---|
| ROSUVASTATIN | $28,580,468 | 4,087,627 |
| ATORVASTATIN | $21,660,928 | 2,777,911 |
| PANTOPRAZOLE | $20,617,705 | 2,730,906 |
| ESOMEPRAZOLE | $16,604,681 | 1,944,967 |
| ESCITALOPRAM | $6,901,139 | 1,625,487 |
| PERINDOPRIL | $10,664,316 | 1,558,520 |
| SERTRALINE | $7,122,111 | 1,554,494 |
| METFORMIN | $11,143,085 | 1,495,150 |
| CEFALEXIN | $6,732,745 | 1,287,081 |
| AMOXICILLIN | $5,103,519 | 1,251,278 |
| AMLODIPINE | $8,156,241 | 1,161,429 |
| APIXABAN | $69,139,138 | 1,105,627 |
| Contributor | Contribution Dollars |
|---|---|
| Australian Government | $4,890,673,542 |
| Patients | $976,260,461 |